Skip Navigation



Carcinogenesis Advance Access published online on February 12, 2009
Carcinogenesis, doi:10.1093/carcin/bgp040
This Article
Right arrow Advance Access manuscript (PDF)
Right arrow All Versions of this Article:
30/4/682    most recent
bgp040v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Khanal, P.
Right arrow Articles by Choi, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Khanal, P.
Right arrow Articles by Choi, H. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Tpl-2 kinase downregulates the activity of p53 and enhances signaling pathways leading to activation of Activator Protein 1 induced by EGF

Prem Khanal1, Kwang-Yeol Lee2, Keon-Wook Kang1, Bong Seok Kang3 and Hong Seok Choi1,*

1 College of Pharmacy, Chosun University, Seosuk-dong, Dong-gu, Gwangju 501-759, South Korea
2 College of Pharmacy, Chonnam National University, Yongbong-dong, Buk-gu, Gwangju 500-757, South Korea
3 Bio-Medical Research Institute, Kyungpook National University Hospital, Daegu 700-721, South Korea

* Address correspondence to: Hong Seok Choi, Tel: 82-62-230-6379; Fax: 507-437-9606; E-mail: chs{at}chosun.ac.kr

Tumor progression locus-2 (Tpl-2) kinase is a member of the mitogen-activated protein kinase (MAPK) kinase kinase family that has been implicated in cellular transformation. The enhanced expression of this protein has been shown to activate both the MAPK and c-Jun N-terminal kinase (JNK) pathways. However, the molecular mechanisms responsible for the oncogenic potential of Tpl-2 are still largely unknown. Here, we showed that Tpl-2 interacted with p53 both in vitro and ex vivo. The overexpression of Tpl-2 inhibited the EGF-induced p53 phosphorylation (Ser15) through upregulating the activity of protein phosphatase 2A (PP2A), which interacted with p53 stimulated by EGF. Also, the EGF-induced p53 activity was suppressed in the Tpl-2-wild-type-transfeted HEK 293 cells, but had no effect in the Tpl-2-mutant (S413A)-transfected cells. Furthermore, introduction of small interfering RNA-Tpl-2 into HEK 293 cells resulted in decreased cell viability compared to only adenovirus-p53-infected cells. In addition, the Tpl-2 wild type, but not Tpl-2 mutant (S413A), showed increased EGF-induced c-fos promoter activity, followed by AP-1 transactivation activity, which was associated with the cell transformation prompted by the H-Ras-Tpl-2-AP-1 signaling axis. These results indicated that the Ser413 of Tpl-2 plays an important role in EGF-induced carcinogenesis as well as inactivation of the p53.

Received September 1, 2008; revised December 24, 2008; accepted February 6, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.